- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gilead Sciences completes purchase of MYR GmbH for 1.45 billion Euros
Foster City: Gilead Sciences, Inc. has recently announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV)...
Foster City: Gilead Sciences, Inc. has recently announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration.
The acquisition provides Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
"Hepcludex is an important new addition to the Gilead portfolio. With this first-in-class therapy for HDV, the most severe form of viral hepatitis, we have the opportunity to address an area of high unmet medical need," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "Gilead has nearly 20 years of experience in innovating and improving therapies for viral hepatitis. We can now build on that with Hepcludex, working with the MYR team to realize the full potential of the therapy for people with HDV worldwide."
As a result of the completion of the merger, MYR has become a wholly owned subsidiary of Gilead.
Hepcludex is an investigational agent, and its safety and efficacy have not been established in the U.S. or in other regions where it has not received regulatory approval. Hepcludex, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751